TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.


Options:
A: Intervention Type: DRUG; Name: inhaled corticosteroids; Assigned to Arm(s): N/A
B: Arm Label: Daily ICS + Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Daily ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Rescue ICS; Type: EXPERIMENTAL; Interventions: Drug: Beclomethasone dipropionate, Drug: Albuterol sulfate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albuterol sulfate | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS | Intervention Type: DRUG; Name: Beclomethasone dipropionate; Assigned to Arm(s): Daily ICS + Rescue ICS, Rescue ICS | Intervention Type: DRUG; Name: Albuterol sulfate; Assigned to Arm(s): Daily ICS, Daily ICS + Rescue ICS, Placebo, Rescue ICS
C: Arm Label: 1 Budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Budesonide | Arm Label: 2 Nedocromil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nedocromil | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 Placebo | Intervention Type: DRUG; Name: Nedocromil; Assigned to Arm(s): 2 Nedocromil | Intervention Type: DRUG; Name: Budesonide; Assigned to Arm(s): 1 Budesonide
D: Arm Label: Ciclesonide 40 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 80 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Ciclesonide 160 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide, Drug: Placebo, Drug: Salbutamol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Salbutamol | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo | Intervention Type: DRUG; Name: Salbutamol; Assigned to Arm(s): Ciclesonide 160 µg, Ciclesonide 40 µg, Ciclesonide 80 µg, Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke
Brief Summary: The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.


Options:
A: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A
C: Arm Label: Combination Clopidogrel and asprin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Asprin and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of clopidogrel and Asprin | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Combination Clopidogrel and asprin | Intervention Type: DRUG; Name: Placebo of clopidogrel and Asprin; Assigned to Arm(s): Asprin and placebo
D: Arm Label: ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: ticagrelor | Arm Label: Acetylsalicylic acid (ASA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetylsalicylic acid (ASA) | Intervention Type: DRUG; Name: ticagrelor; Assigned to Arm(s): ticagrelor | Intervention Type: DRUG; Name: Acetylsalicylic acid (ASA); Assigned to Arm(s): Acetylsalicylic acid (ASA)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Double-Blind, Randomized, Multi-Center, and Active Controlled Trial for Efficacy and Safety of Cilostazol in Acute Ischemic Stroke
Brief Summary: The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.


Options:
A: Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
B: Arm Label: Aggrenox Capsule; Type: OTHER; Interventions: Drug: Aggrenox capsule | Arm Label: Acetylsalicylic Acid (ASA) 81 mg Tablet; Type: OTHER; Interventions: Other: Acetylsalicylic Acid (ASA) | Intervention Type: DRUG; Name: Aggrenox capsule; Assigned to Arm(s): Aggrenox Capsule | Intervention Type: OTHER; Name: Acetylsalicylic Acid (ASA); Assigned to Arm(s): Acetylsalicylic Acid (ASA) 81 mg Tablet
C: Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ASA 100 mg qd; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Study of Improving Treatment for the Most Severely Ill With Schizophrenia
Brief Summary: This is a 9 week, multicentre, randomized, double-blind, placebo-controlled trial with two parallel groups. There is also an open-label extension phase of 18 weeks. Both medications to be used in the study, clozapine and risperidone, are fully approved for the treatment of schizophrenia.


Options:
A: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
B: Arm Label: Aripiprazole depot 300 or 400 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 300 or 400 mg, Drug: Placebo tablets | Arm Label: Aripiprazole 10-30 mg orally; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole 10-30 mg orally, Drug: Placebo depot | Arm Label: Aripiprazole depot 25 or 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole depot 25 or 50 mg, Drug: Placebo tablets | Intervention Type: DRUG; Name: Aripiprazole depot 300 or 400 mg; Assigned to Arm(s): Aripiprazole depot 300 or 400 mg | Intervention Type: DRUG; Name: Aripiprazole 10-30 mg orally; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Aripiprazole depot 25 or 50 mg; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg | Intervention Type: DRUG; Name: Placebo depot; Assigned to Arm(s): Aripiprazole 10-30 mg orally | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): Aripiprazole depot 25 or 50 mg, Aripiprazole depot 300 or 400 mg
C: Arm Label: A - 10 mg loxapine q 4 h x 3 (30 mg total); Type: EXPERIMENTAL; Interventions: Drug: A - 10 mg loxapine q 4 h x 3 (30 mg total) | Arm Label: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Type: EXPERIMENTAL; Interventions: Drug: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Arm Label: C - 5 mg loxapine q 4 h x 3 (15 mg total); Type: EXPERIMENTAL; Interventions: Drug: C - 5 mg loxapine q 4 h x 3 (15 mg total) | Arm Label: D - inhaled placebo q 4 h x 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: D - inhaled placebo q 4 h x 3 | Intervention Type: DRUG; Name: A - 10 mg loxapine q 4 h x 3 (30 mg total); Assigned to Arm(s): A - 10 mg loxapine q 4 h x 3 (30 mg total) | Intervention Type: DRUG; Name: B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total); Assigned to Arm(s): B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total) | Intervention Type: DRUG; Name: C - 5 mg loxapine q 4 h x 3 (15 mg total); Assigned to Arm(s): C - 5 mg loxapine q 4 h x 3 (15 mg total) | Intervention Type: DRUG; Name: D - inhaled placebo q 4 h x 3; Assigned to Arm(s): D - inhaled placebo q 4 h x 3
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Study of Improving Treatment for the Most Severely Ill With Schizophrenia
Brief Summary: This is a 9 week, multicentre, randomized, double-blind, placebo-controlled trial with two parallel groups. There is also an open-label extension phase of 18 weeks. Both medications to be used in the study, clozapine and risperidone, are fully approved for the treatment of schizophrenia.


Options:
A: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: aripiprazole | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B
D: Arm Label: Risperidone, Intensive; Type: EXPERIMENTAL; Interventions: Drug: risperidone | Arm Label: risperidone, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Arm Label: olanzapine, intensive; Type: EXPERIMENTAL; Interventions: Drug: olanzapine | Arm Label: olanzapine, basic; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: aripiprazole, intensive; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: aripiprazole, basiv; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): Risperidone, Intensive, risperidone, basic | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): olanzapine, basic, olanzapine, intensive | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): aripiprazole, basiv, aripiprazole, intensive

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: International Study of Improving Treatment for the Most Severely Ill With Schizophrenia
Brief Summary: This is a 9 week, multicentre, randomized, double-blind, placebo-controlled trial with two parallel groups. There is also an open-label extension phase of 18 weeks. Both medications to be used in the study, clozapine and risperidone, are fully approved for the treatment of schizophrenia.


Options:
A: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Risperidone, long-acting injectable; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: main antipsychotic medication and placebo | Intervention Type: DRUG; Name: 2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: main antipsychotic medication and placebo; Assigned to Arm(s): 2
D: Arm Label: sulpiride plus amisulpride; Type: EXPERIMENTAL; Interventions: Drug: full-dose amisulpride | Arm Label: full-dose amisulpride; Type: ACTIVE_COMPARATOR; Interventions: Drug: full-dose amisulpride | Intervention Type: DRUG; Name: full-dose amisulpride; Assigned to Arm(s): full-dose amisulpride, sulpiride plus amisulpride

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone Long Acting: A Healthcare Resource Utilization Pilot Study
Brief Summary: The primary objective of this pilot study is to evaluate the impact of switching 30 subjects from an existing antipsychotic to risperidone long acting on healthcare resource utilization. The study will be a ten month open-label, 'mirror-image', pilot study. Healthcare resource utilization during the 10 months prior to starting risperidone long acting will be retrospectively collected for all subjects (period A) at the beginning of the study. The utilization of direct medical resources will also be collected for 10 months after initiation of risperidone long acting (period B). In this design the patients will serve as their own control.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: IM risperidone | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral antipsychotic medication | Intervention Type: DRUG; Name: IM risperidone; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: oral antipsychotic medication; Assigned to Arm(s): Arm 2
B: Intervention Type: DRUG; Name: atypical antipsychotics:oral vs. long-acting route; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Family Psychoeducation; Assigned to Arm(s): N/A
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: BL - 1020 | Arm Label: III; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: IV; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): I | Intervention Type: DRUG; Name: BL - 1020; Assigned to Arm(s): II | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): III | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): IV
D: Arm Label: Risperidone LAI; Type: OTHER; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone LAI

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Nosocomial Infection in Cardiac Surgery by Decontamination of the Naso- and Oropharynx With Chlorhexidine. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Brief Summary: Does chlorhexidine gluonate, a simple broad-spectrum antimicrobial agent with virtually no adverse-effects lower the incidence of NI after cardiac surgery, especially with respect to LTI and SSI?


Options:
A: Arm Label: Biotene OralBalance® gel Arm; Type: EXPERIMENTAL; Interventions: Drug: Biotene OralBalance® gel | Arm Label: Sterile Water Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Sterile Water moisten cotton tipped applicator | Intervention Type: DRUG; Name: Biotene OralBalance® gel; Assigned to Arm(s): Biotene OralBalance® gel Arm | Intervention Type: OTHER; Name: Sterile Water moisten cotton tipped applicator; Assigned to Arm(s): Sterile Water Arm
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chlorhexidine gel | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Intervention Type: DRUG; Name: Chlorhexidine gel; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Chlorhexidine gluconate (drug) vs placebo; Assigned to Arm(s): N/A
D: Arm Label: Pre-intubation CHX; Type: EXPERIMENTAL; Interventions: Procedure: Pre-intubation CHX | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Control | Intervention Type: PROCEDURE; Name: Pre-intubation CHX; Assigned to Arm(s): Pre-intubation CHX | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Nosocomial Infection in Cardiac Surgery by Decontamination of the Naso- and Oropharynx With Chlorhexidine. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Brief Summary: Does chlorhexidine gluonate, a simple broad-spectrum antimicrobial agent with virtually no adverse-effects lower the incidence of NI after cardiac surgery, especially with respect to LTI and SSI?


Options:
A: Arm Label: Toothbrushing with a manual brush; Type: EXPERIMENTAL; Interventions: Device: Toothbrushing with a manual brush | Arm Label: No toothbrushing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Toothbrushing with a manual brush; Assigned to Arm(s): Toothbrushing with a manual brush
B: Intervention Type: DRUG; Name: Chlorhexidine gluconate (drug) vs placebo; Assigned to Arm(s): N/A
C: Arm Label: Raspall; Type: EXPERIMENTAL; Interventions: Procedure: Toothbrushing | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Toothbrushing; Assigned to Arm(s): Raspall
D: Arm Label: povidone iodine; Type: EXPERIMENTAL; Interventions: Drug: povidone iodine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: povidone iodine; Assigned to Arm(s): povidone iodine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Controlled Assessment of Once-Daily Controlled Release COREG CR vs Twice-Daily COREG Immediate Release(IR)on Measures of Compliance and Quality of Life in Patients With Heart Failure and Left Ventricular Systolic Dysfunction
Brief Summary: The purpose of this study is to compare dosing compliance between study patients taking controlled release carvedilol once a day, and study patients taking immediate release carvedilol (Coreg) twice a day.


Options:
A: Intervention Type: DRUG; Name: carvedilol; Assigned to Arm(s): N/A
B: Arm Label: Diabetes Medication Choice decision aid; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Medication Choice decision aid | Arm Label: Usual Care; Type: OTHER; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Diabetes Medication Choice decision aid; Assigned to Arm(s): Diabetes Medication Choice decision aid | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Arm 1: Collaborative Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Interventions | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Collaborative Care Interventions; Assigned to Arm(s): Arm 1: Collaborative Care Intervention
D: Intervention Type: BEHAVIORAL; Name: Set of supportive tools/measures vs. standard care; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Lifestyle Intervention vs Gastric Bypass on Various Comorbidities
Brief Summary: This follow up study (\>1 year) aims to compare the effects of lifestyle intervention and gastric by pass surgery on various comorbidities associated with morbid obesity.


Options:
A: Arm Label: EndoBarrier Device; Type: EXPERIMENTAL; Interventions: Device: EndoBarrier Device, Behavioral: Diet & Lifestyle Counseling | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diet & Lifestyle Counseling | Intervention Type: DEVICE; Name: EndoBarrier Device; Assigned to Arm(s): EndoBarrier Device | Intervention Type: BEHAVIORAL; Name: Diet & Lifestyle Counseling; Assigned to Arm(s): Control, EndoBarrier Device
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Biliopancreatic diversion with Duodenal switch | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laparoscopic Roux-en-Y Gastric Bypass | Intervention Type: PROCEDURE; Name: Laparoscopic Biliopancreatic diversion with Duodenal switch; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Laparoscopic Roux-en-Y Gastric Bypass; Assigned to Arm(s): 2
C: Arm Label: Bariatric surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Bariatric surgery | Arm Label: Intensive lifestyle intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Bariatric surgery | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: sleeve gastrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Roux-Y-gastric bypass | Intervention Type: PROCEDURE; Name: sleeve gastrectomy; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Roux-Y-gastric bypass; Assigned to Arm(s): B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Brief Dental Office Intervention With Tobacco Quitline
Brief Summary: The novel and exploratory nature of this intervention relates to the concept of incorporating patient-specific oral health information obtained during a dental hygiene visit into the tobacco quitline counseling. Linking the patient-specific oral health information obtained during the dental hygiene visit to the tobacco quitline counseling will close the therapeutic loop for oral health professionals and make them a focal point for the tobacco use intervention without increasing clinical burden.


Options:
A: Intervention Type: DRUG; Name: zyban; Assigned to Arm(s): N/A
B: Arm Label: Group I (varenicline and placebo); Type: EXPERIMENTAL; Interventions: Other: Placebo, Other: Tobacco Cessation Counseling, Drug: Varenicline | Arm Label: Group II (placebo, nicotine patch and lozenge); Type: PLACEBO_COMPARATOR; Interventions: Drug: Nicotine Lozenge, Drug: Nicotine Patch, Other: Placebo, Other: Tobacco Cessation Counseling | Intervention Type: DRUG; Name: Nicotine Lozenge; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: OTHER; Name: Tobacco Cessation Counseling; Assigned to Arm(s): Group I (varenicline and placebo), Group II (placebo, nicotine patch and lozenge) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Group I (varenicline and placebo)
C: Intervention Type: BEHAVIORAL; Name: Telephone quitline; Assigned to Arm(s): N/A
D: Arm Label: Cohort A; Type: EXPERIMENTAL; Interventions: Procedure: Samples collection, Behavioral: Tobacco and alcohol status follow-up | Arm Label: Cohort B; Type: EXPERIMENTAL; Interventions: Procedure: Samples collection, Behavioral: Psychological and Sociological evaluation, Behavioral: Intensive and sustained smoking cessation program, Behavioral: Tobacco and alcohol status follow-up | Arm Label: Cohort C; Type: EXPERIMENTAL; Interventions: Procedure: Samples collection, Behavioral: Tobacco and alcohol status follow-up | Intervention Type: PROCEDURE; Name: Samples collection; Assigned to Arm(s): Cohort A, Cohort B, Cohort C | Intervention Type: BEHAVIORAL; Name: Psychological and Sociological evaluation; Assigned to Arm(s): Cohort B | Intervention Type: BEHAVIORAL; Name: Intensive and sustained smoking cessation program; Assigned to Arm(s): Cohort B | Intervention Type: BEHAVIORAL; Name: Tobacco and alcohol status follow-up; Assigned to Arm(s): Cohort A, Cohort B, Cohort C

Answer: C